Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world registry study of Xinsuning capsule for atrial and ventricular premature beats
ChiCTR2100051225Phase 4Recruiting
- Sponsor
- Beijing Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of xinsuning in atrial extrasystole (AES) and Premature ventricular complexes (PVC), sponsored by Beijing Hospital. Primary endpoints: Reduction of total frequency of premature beats detected by 24-hour ambulatory electrocardiogram and Remission of premature beat-related symptoms. Started Sep 2021; status: recruiting.
02
Drugs
xinsuning
03
Conditions
atrial extrasystole (AES)Premature ventricular complexes (PVC)
Beyond the preview
Go deeper on ChiCTR2100051225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051225.